Corporate Social Responsibility | Business Wire | PR NewsWire | Marketwire | Realwire | ACN/JCN newswire | 247pressrelease | PRWeb

Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration

Posted : Mon, 09 Nov 2009 10:27:38 GMT
Author : Bend Research Inc.
Category : Press Release
News Alerts by Email ( click here )
News | Home
BEND, Oregon, November 9 /PRNewswire/ -- Bend Research Inc., a company with more than 30 years of experience in applying innovative pharmaceutical technologies to help clients solve their most difficult scientific and technical problems, announced today that it has entered into a collaboration with Vertex Pharmaceuticals Incorporated, a global biotechnology company headquartered in Cambridge, MA.
Through this new collaboration, Vertex will utilize Bend's formulation development and manufacturing services for specific projects and clinical trials, with the goals of both enhancing the delivery of Vertex compounds and supporting the progression of certain Vertex product candidates through clinical development.
The collaboration between Bend Research and Vertex is designed to leverage the fundamental scientific capabilities of each company to solve formulation and process-development challenges and to produce commercial drug products that are optimized for therapeutic benefit.
"It's a great opportunity for both companies," Bend Research CEO Rod Ray explained. "We are excited to be working with Vertex. We share their commitment to delivering breakthrough therapies based on cutting-edge science. Having two great teams working side by side is a powerful combination - we look forward to a long and fruitful relationship."
Vertex's Executive Vice President of Global Research and Development and Chief Scientific Officer, Peter Mueller, added, "Our collaboration with Bend Research exemplifies Vertex's commitment to the treatment of serious diseases through cutting-edge science and innovative technologies. We believe Bend's technologies and expertise will provide Vertex with important scientific capabilities that will support our drug development efforts."
Bend Research is making its multidisciplinary team of scientists and engineers available to companies for solving tough formulation and development problems. Bend Research prides itself in offering fast, innovative solutions.
Since late 2008, Bend Research has been rapidly expanding its line-up of industrial partners. Customers that have benefitted from Bend Research's proprietary technology and unique formulation expertise include some two dozen major pharmaceutical companies, mid-size pharmas, and biotech companies around the globe.
About Bend Research Inc.
Bend Research has more than 30 years of experience in helping clients solve their most difficult scientific and technical problems. This success is based on the company's ability to develop, advance and commercialize pharmaceutical technologies. The firm develops innovative drug-delivery solutions from a solid base of fundamental understanding. Bend Research provides formulation and dosage-form support, assists in process development and optimization, manufactures clinical trial quantities of drug candidates in its cGMP facility, and advances promising drug candidates from conception through to commercialization.
The company's flexible, client-focused business model and collaborative approach to working with its customers enable long-term alliances with clients focused on value creation.
Bend Research has more than 140 employees based in three state-of-the-art facilities in Bend, Oregon, USA.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small-molecule drugs for serious diseases. The company's strategy is to commercialize products independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.
    Contact:

    Dana Settell
    Bend Research Inc.
    64550 Research Road
    Bend, OR 97701

    Phone: +1(541)-382-4100
    Fax: +1(541)-382-2713
    E-mail: settell@bendres.com

SOURCE Bend Research Inc.

Copyright © 2008 PR Newswire. All rights reserved.

Share/Save/Bookmark

Article : Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
Print this article
Share this article

Stay Updated

News gadget on your Google homepage
Subscribe to a news feed in Google Reader



Related News

Tesco Mobile Network Customers to Get the iPhone
LONDON, UNITED KINGDOM -- 11/25/09 -- Tesco Mobile through its joint venture partnership with O2 is pleased to announce that it will shortly introduce iPhone 3G and iPhone 3GS in Tesco Phone Shops and online through Tesco Direct in the UK.

Fitch SMARTView: No Additional Classes of U.S. Credit Card ABS Portfolio Placed 'Under Analysis'
NEW YORK - Following its monthly surveillance review of U.S. Credit Card asset-backed securities (ABS) transactions, Fitch Ratings has not placed any additional U.S. credit card ABS transactions 'Under Analysis'. Five hundred and thirty classes of U.S. credit card ABS transac

Fitch Affirms Brownsville, Texas GOs at 'A+'; Upgrades BCIC's Sales Tax Bonds to 'A+'
NEW YORK - As part of ongoing surveillance, Fitch Ratings affirms its 'A+' rating on the city's approximately $162 million of outstanding general obligation (GO) and combination tax and revenue certificates of obligation (CO) bonds. The Rating Outlook is revised to Stable from Positiv

Grady P. Andrews, P.E., Joins Baker as New Mid-Atlantic Construction Services Manager for Virginia, West Virginia and Maryland
RICHMOND, Va. - Grady P. Andrews, P.E., has been appointed Mid-Atlantic construction services manager serving the states of Maryland, Virginia and West Virginia for Michael Baker Jr., Inc., an engineering unit of Michael Baker Corporation (NYSE Amex:BKR). He will be responsible for co

Westar Energy Declares Dividends
TOPEKA, KS -- 11/25/09 -- The Westar Energy, Inc. (NYSE: WR) Board of Directors today declared a quarterly dividend of 30 cents per share payable Jan. 4, 2010 on the company's common stock. The board also declared regular quarterly divide..

The Advisory Board Company to Present at 21st Annual Piper Jaffray Health Care Conference
WASHINGTON, Nov. 25 -- The Advisory Board Company (Nasdaq: ABCO) announced today that it will participate in the 21st Annual Piper Jaffray Health Care Conference in New York City. Speaking at the conference, on December 2, 2009 at 3:00 PM (EST), will be the Compa...

FXDD Announces Expansion into New Offices at 7 World Trade Center
a href= http://www.fxdd.com onclick= linkClick( this.href ); target= _blank title= FXDD FXDD/a is proud to announce the acquisition of a magnificent new office space at 7 World Trade Center./I/P PNew York, NY (Vocus) November 25, 2009 -- a href= http://www.fxdd.com onclick= li...

Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 
Follow The Earth Times
Subscribe to RSS Follow Earth Times on TwitterNews by email
Share/Save/Bookmark
 
 



 
Subscribe to free Earthtimes
News Alerts by Email Click here
For RSS Feeds Click here
or Create your own RSS

Add to Google Toolbar
Breaking News
Press Releases

 


The Earth Times
News Category

© 2009 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.